What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants receiving AWT020 once every two weeks or longer at designated dose levels”In the company’s words, NCT06092580 on ClinicalTrials.gov
- Tested for
- Advanced Cancer, Advanced Cancers (Solid Tumors)
- Main trialPhase 1
- “The aims of this clinical trial are (1) to assess the safety of AWT020 at different dose levels; (2) to determine the pharmacokinetics and pharmacodynamics of AWT020 in subjects with locally advanced or metastatic cancer who have failed standard therapy.”In the company’s words, NCT06092580 on ClinicalTrials.gov
Other drugs for Advanced Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Jan 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Jun 2026 | Phase 1 Study of AWT020 in Advanced Cancer | |
| Phase 1Recruiting | Jan 2029 | A Study of AWT020 in Participants With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026